ATNX News and Press, Athenex Inc. From 03/01/21

Image source: The Motley Fool. Athenex, Inc. (NASDAQ: ATNX) Q4 2020 Earnings Call Mar 1, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Athenex, Inc. (ATNX) Q4 2020 Earnings Call Transcript

The following slide deck was published by Athenex, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Athenex, Inc. 2020 Q4 - Results - Earnings Call Presentation

Athenex, Inc. (ATNX) Q4 2020 Earnings Conference Call March 1, 2021 08:00 ET Company Participants Steve Rubis - Senior Director of Investor Relations Johnson Lau - Chief Executive Officer Jeff Yordon - Chief Operating Officer Rudolf Kwan - Chief Medical Officer Randoll Sze - Chief Financial O...

Gainers: Morphic (MORF) +106%.Aemetis (AMTX) +58%.SOS (SOS) +43%.Canaan (CAN) +41%.electroCore (ECOR) +37%.Vector Acquisition (VACQU) +37%.The9 (NCTY) +36%.One Stop Systems (OSS) +30%.HCI Group (HCI) +29%.ZK International (ZKIN) +27%.Losers: Athenex (ATNX) -52%.O...

Gainers: Morphic (MORF) +104%, electroCore (ECOR) +51%, Apollo Endosurgery (APEN) +24%, ASLAN Pharmaceuticals (ASLN) +23%, Satsuma Pharmaceuticals (STSA) +19%.Losers: Athenex (ATNX) -51%, Ontrak (OTRK) -48%, CorMedix (...

Athenex (ATNX) -55% on Q4 earnings release and on FDA rejection of oral paclitaxel application in breast cancer.Xtant Medical Holdings (XTNT) -16%.PLx Pharma (PLXP) -9% after FDA OKs PLx Pharma's Vazalore applications.Lixte Biotechnology Holdings (LIXT) -12%.Amer...

Athenex (ATNX) Q4 results:Revenues: $21.8M (-36.6%), beats estimates by $1.09M.Net Loss: ($49.5M), compared with $21.73M last year; Loss Per Share: ($0.53)Shares down nearly 22% premarket.Athenex also received a complete response letter ((CRL)) from the FDA regarding ...

Athenex (ATNX) slumps 22% premarket after receiving a complete response letter ((CRL)) from the FDA regarding its New Drug Application ((NDA)) for oral paclitaxel plus encequidar for the treatment of metastatic breast cancer.The FDA indicated that the review cycle is complete a...

Athenex (ATNX): Q4 GAAP EPS of -$0.53 misses by $0.09.Revenue of $21.8M (-36.6% Y/Y) beats by $1.09M.Shares -21.6% PM.Press Release For further details see: Athenex EPS misses by $0.09, beats on revenue

Receipt of Complete Response Letter from the FDA for Oral Paclitaxel Plus Encequidar Klisyri® (tirbanibulin) received FDA approval and launched commercially on February 18, 2021 The New England Journal of Medicine published Phase III trial data on the efficacy and safety of K...